Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Systematic Review Article

血浆簇蛋白作为阿尔茨海默氏病的潜在生物标记物-系统评价和荟萃分析

卷 16, 期 11, 2019

页: [1018 - 1027] 页: 10

弟呕挨: 10.2174/1567205016666191024141757

open access plus

摘要

背景：据报道血浆簇蛋白与阿尔茨海默氏病（AD）的病理，患病率，严重程度和快速的临床进展有关。但是，血浆簇蛋白是否可以用作AD的生物标志物仍然不一致甚至矛盾。 目的：我们进行了这项研究，以评估血浆簇蛋白作为AD生物标志物的潜力。 方法：系统搜索PubMed，Embase和Cochrane数据库，以研究血浆簇蛋白水平与AD诊断，风险和疾病严重程度之间的关系。我们还比较了AD组和对照组之间的脑脊液（CSF）簇蛋白水平的差异。我们使用标准化均值差，Pearson线性回归模型和Cox回归模型转换和合并了数据。 结果：总共包括17篇文章和7228个人，包括公元1936年。质量范围从中到高。 AD组和对照组之间的血浆簇蛋白没有差异（SMD = 0.19 [-0.10，0.48]，p = 0.20）。血浆簇蛋白水平与风险（RR = 1.03 [0.97-1.09]，p = 0.31），MMSE评分（R = 0.33 [-0.06，0.71]，p = 0.09）和综合神经心理学测量值（R）无关。 ＝ AD的0.21 [-0.20，0.63]，p ＝ 0.31）。此外，AD组和对照组之间的CSF簇蛋白没有差异（SMD = 1.94 [-0.49，4.37]，p = 0.12）。 结论：我们的荟萃分析表明血浆簇蛋白水平与AD的诊断，风险和疾病严重程度之间没有关系，AD组和对照组之间的CSF簇蛋白没有差异。总体而言，根据汇总结果，没有证据支持血浆簇蛋白作为AD的生物标志物。

关键词: 簇蛋白，阿尔茨海默氏病，痴呆，生物标志物，系统评价，荟萃分析。

« Previous Next »
[1]
Frankish H, Horton R. Prevention and management of dementia: a priority for public health. Lancet (London, England) 390(10113): 2614-5.(2017);
[2]
Alzheimer’s A. 2018 Alzheimer’s disease facts and figures. Alzheimers & Dementia 14(3): 367-425.(2018);
[3]
Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 148(6): 1204-22.(2012);
[4]
Cao J, Hou J, Ping J, Cai D. Advances in developing novel therapeutic strategies for Alzheimer’s disease. Mol Neurodegener 13(1): 64.(2018);
[5]
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13(6): 614-29.(2014);
[6]
Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289(16): 2094-103.(2003);
[7]
Morris E, Chalkidou A, Hammers A, Peacock J, Summers J, Keevil S. Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 43(2): 374-85.(2016);
[8]
Hill E, Goodwill AM, Gorelik A, Szoeke C. Diet and biomarkers of Alzheimer’s disease: a systematic review and meta-analysis. Neurobiol Aging 76: 45-52.(2019);
[9]
Wilson MR, Zoubeidi A. Clusterin as a therapeutic target. Expert Opin Ther Targets 21(2): 201-13.(2017);
[10]
Islam K, Damiati S, Sethi J, Suhail A, Pan G. Development of a label-free immunosensor for clusterin detection as an alzheimer's biomarker. Sensors (Basel, Switzerland) 18(1) pii: E308(2018);
[11]
Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer’s disease. Brain Res Rev 61(2): 89-104.(2009);
[12]
Wu ZC, Yu JT, Li Y, Tan L. Clusterin in Alzheimer’s disease. Advances in clinical chemistry 56: 155-73.(2012);
[13]
Gouras GK, Olsson TT, Hansson O. Beta-amyloid peptides and amyloid plaques in Alzheimer’s disease. Neurotherapeutics 12(1): 3-11.(2015);
[14]
Yu JT, Tan L. The role of clusterin in Alzheimer’s disease: pathways, pathogenesis, and therapy. Mol Neurobiol 45(2): 314-26.(2012);
[15]
Nelson AR, Sagare AP, Zlokovic BV. Role of clusterin in the brain vascular clearance of amyloid-beta. Proc Natl Acad Sci USA 114(33): 8681-2.(2017);
[16]
Li X, Ma Y, Wei X, Li Y, Wu H, Zhuang J, et al. Clusterin in Alzheimer’s disease: a player in the biological behavior of amyloid-beta. Neurosci Bull 30(1): 162-8.(2014);
[17]
Lidstrom AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K. Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer’s disease. Exp Neurol 154(2): 511-21.(1998);
[18]
May PC, Lampert-Etchells M, Johnson SA, Poirier J, Masters JN, Finch CE. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer’s disease and in response to experimental lesions in rat. Neuron 5(6): 831-9.(1990);
[19]
Zhu R, Liu X, He Z. Association between CLU gene rs11136000 polymorphism and Alzheimer’s disease. Neurol Sci 39(4): 679-89.(2018);
[20]
Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Transl Psychiatry 41(10): 1094-9.(2009);
[21]
Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41(10): 1088-93.(2009);
[22]
Schrijvers EMC, Koudstaal PJ, Hofman A, Breteler MMB. Plasma clusterin and the risk of Alzheimer disease. JAMA 305(13): 1322-6.(2011);
[23]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 151(4): 264-9.(2009);
[24]
Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC 14: 45.(2014);
[25]
Dukic L, Simundic AM, Martinic-Popovic I, Kackov S, Diamandis A, Begcevic I, et al. The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia. Clin Biochem 49(3): 213-8.(2016);
[26]
Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, et al. A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. Neurobiol Aging 37: 208. .e1-.e9(2016);
[27]
Hsu JL, Lee WJ, Liao YC, Wang SJ, Fuh JL. The clinical significance of plasma clusterin and Abeta in the longitudinal follow-up of patients with Alzheimer’s disease. Alzheimers Res Ther 9(1): 91.(2017);
[28]
Ijsselstijn L, Dekker LJM, Koudstaal PJ, Hofman A, Sillevis SPAE, Breteler MMB, et al. Serum clusterin levels are not increased in presymptomatic Alzheimers disease. J Proteome Res 10(4): 2006-10.(2011);
[29]
Mukaetova-Ladinska EB, Abdel-All Z, Andrade J, Alves da Silva J, O’Brien JT, Kalaria RN. Plasma and platelet clusterin ratio is altered in Alzheimer’s disease patients with distinct neuropsychiatric symptoms: findings from a pilot study. Int J Geriatr Psychiatry 30(4): 368-75.(2015);
[30]
Mullan GM, McEneny J, Fuchs M, McMaster C, Todd S, McGuinness B, et al. Plasma clusterin levels and the rs11136000 genotype in individuals with mild cognitive impairment and Alzheimer’s disease. Curr Alzheimer Res 10(9): 973-8.(2013);
[31]
Richens JL, Vere KA, Light RA, Soria D, Garibaldi J, Smith AD, et al. Practical detection of a definitive biomarker panel for Alzheimer’s disease; comparisons between matched plasma and cerebrospinal fluid. Int J Mol Epidemiol Genet 5(2): 53-70.(2014);
[32]
Schürmann B, Wiese B, Bickel H, Weyerer S, Riedel-Heller SG, Pentzek M, et al. Association of the Alzheimer’s disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis 25(3): 421-4.(2011);
[33]
Silajdžić E, Minthon L, Björkqvist M, Hansson O. No Diagnostic value of plasma clusterin in Alzheimer’s disease. PLoS One 7(11)(2012);
[34]
Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67(7): 739-48.(2010);
[35]
Vishnu VY, Modi M, Sharma S, Mohanty M, Goyal MK, Lal V, et al. Role of plasma clusterin in Alzheimer’s disease-a pilot study in a tertiary hospital in Northern India. PLoS One 11(11) e0166369(2016);
[36]
Xing YY, Yu JT, Cui WZ, Zhong XL, Wu ZC, Zhang Q, et al. Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer’s disease. J Alzheimers Dis 29(3): 515-9.(2012);
[37]
Lidström AM, Hesse C, Rosengren L, Fredman P, Davidsson P, Blennow K. Normal levels of clusterin in cerebrospinal fluid in Alzheimer’s disease, and no change after acute ischemic stroke. J Alzheimers Dis 3(5): 435-42.(2001);
[38]
Weinstein G, Beiser AS, Preis SR, Courchesne P, Chouraki V, Levy D, et al. Plasma clusterin levels and risk of dementia, Alzheimer’s disease, and stroke. Alzheimer’s and dementia: diagnosis. Assess Dis Monit 3: 103-9.(2016);
[39]
Jongbloed W, Van Dijk KD, Mulder SD, Van De Berg WDJ, Blankenstein MA, Van Der Flier W, et al. Clusterin levels in Plasma Predict Cognitive Decline and Progression to Alzheimer’s Disease. J Alzheimers Dis 46(4): 1103-10.(2015);
[40]
Haight T, Bryan RN, Meirelles O, Tracy R, Fornage M, Richard M, et al. Associations of plasma clusterin and Alzheimer’s disease-related MRI markers in adults at mid-life: The CARDIA Brain MRI sub-study. PLoS One 13(1) e0190478(2018);
[41]
Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, Guntert A, et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 59(1): 212-7.(2012);
[42]
Yang C, Wang H, Li C, Niu H, Luo S, Guo X. Association between clusterin concentration and dementia: a systematic review and meta-analysis. Metab Brain Dis 34(1): 129-40.(2019);
[43]
Dubois B, Padovani A, Scheltens P, Rossi A, Dell’Agnello G. Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges. J Alzheimers Dis 49(3): 617-31.(2016);
[44]
Pinto TCC, Machado L, Bulgacov TM, Rodrigues-Junior AL, Costa MLG, Ximenes RCC, et al. Is the montreal cognitive assessment (moca) screening superior to the mini-mental state examination (mmse) in the detection of mild cognitive impairment (mci) and Alzheimer’s disease (AD) in the elderly? Int Psychogeriatr 31(4): 491-504.(2019);
[45]
Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6(3): 131-44.(2010);
[46]
Wang P, Chen K, Gu Y, Guo Q, Hong Z, Zhao Q. beta-Amyloid Upregulates Intracellular Clusterin but not Secretory Clusterin in Primary Cultured Neurons and APP Mice. Curr Alzheimer Res 14(11): 1207-14.(2017);
[47]
Esteban JA. Living with the enemy: a physiological role for the beta-amyloid peptide. Trends Neurosci 27(1): 1-3.(2004);
[48]
Leo G, Genedani S, Filaferro M, Carone C, Andreoli N, Astancolle S, et al. Hyper-homocysteinemia alters amyloid peptide-clusterin interactions and neuroglial network morphology and function in the caudate after intrastriatal injection of amyloid peptides. Curr Alzheimer Res 4(3): 305-13.(2007);

Rights & Permissions Print Cite
Article Metrics
40
6
1
© 2024 Bentham Science Publishers | Privacy Policy